API

Glimepiride is a third-generation oral sulfonylurea antidiabetic agent used for the treatment of type 2 diabetes mellitus. It works by stimulating insulin secretion from pancreatic β-cells and enhancing peripheral insulin sensitivity, thereby helping to control blood glucose levels.

Glimepiride is widely used as monotherapy or in combination with other antidiabetic drugs like Metformin or Pioglitazone. Manufactured under cGMP-compliant conditions, Glimepiride API meets major pharmacopeial standards (USP/EP/BP/IP) and offers high purity, excellent stability, and consistent particle size—ideal for tablet formulation.